DynamX Bioadaptor Hong Kong Registry

计划入组 50 人 · 首次发布于 2020 年 7 月 23 日

DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Coronary Bioadaptor System

计划入组 5,000 人 · 首次发布于 2023 年 10 月 10 日

DYNAMX Bioadaptor ImplanTation for the trEatment of Complex Coronary Lesions

计划入组 55 人 · 首次发布于 2022 年 7 月 19 日

Dynamin activator

FVII (DNARX)

Mepolizumab Biosimilar (DNARX)

Dynavax GmbH

Germany

DYNAMIC PHARMACEUTICALS

India

Dynarex Corporation

United States

Elixir Medical's DynamX Bioadaptor Meets Primary Endpoint in INFINITY-SWEDEHEART Trial

Elixir Medical's DynamX Bioadaptor Achieves 48% Reduction in Coronary Events in Landmark Trial

Elixir Medical's DynamX Bioadaptor Shows Sustained Clinical Benefits Over Drug-Eluting Stents at Three Years